Briacell Therap (NASDAQ:BCTX) Short Interest Up 84.6% in May

Briacell Therap (NASDAQ:BCTX) saw a significant growth in short interest in May. As of May 29th, there was short interest totaling 867,761 shares, a growth of 84.6% from the May 14th total of 470,162 shares. Based on an average trading volume of 269,245 shares, the days-to-cover ratio is currently 3.2 days. Currently, 10.0% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Wall Street Zen raised shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a research note on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Briacell Therap presently has a consensus rating of “Sell”.

Briacell Therap Price Performance

BCTX traded up $0.10 on Monday, reaching $2.87. The company’s stock had a trading volume of 33,380 shares, compared to its average volume of 367,750. Briacell Therap has a 1 year low of $2.60 and a 1 year high of $32.40. The business’s 50 day moving average is $3.82 and its 200 day moving average is $5.31. The stock has a market cap of $24.97 million, a price-to-earnings ratio of -0.12 and a beta of 1.21.

Briacell Therap (NASDAQ:BCTX) last posted its quarterly earnings data on Tuesday, June 9th. The company reported ($0.99) earnings per share (EPS) for the quarter.

Institutional Trading of Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC acquired a new stake in shares of Briacell Therap (NASDAQ:BCTX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap at the end of the most recent reporting period. Institutional investors and hedge funds own 15.42% of the company’s stock.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.